Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa.
Journal: Molecular therapy. Advances
Published: November 25, 2025
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader.
Journal: Nature communications
Published: December 06, 2024
Showing 1-3 of 3
Last Updated: 09/26/2026